J&J is latest company trying to get on Trump’s good side with big U.S. investment

Published 03/21/2025, 10:35 AM
© Reuters.

Investing.com -- Pharmaceutical giant Johnson & Johnson became the latest company to announce a massive investment in the U.S. to appease President Donald Trump.

Johnson & Johnson (NYSE:JNJ) announced Friday that it plans to invest more than $55 billion into the U.S. economy over the next four years.

It’s the latest commitment by major U.S. companies, contributing to approximately $1 trillion in domestic manufacturing expansion.

In February, President Trump reportedly warned top pharma executives of potential tariffs if they don’t move manufacturing to the U.S. and declined to commit to weakening the Inflation Reduction Act’s drug price negotiation program.

Johnson & Johnson said the investment represents a 25% increase compared to the prior four years.

“Our increased U.S. investment begins with the ground-breaking of a high-tech facility in North Carolina that will not only add U.S.-based jobs but manufacture cutting edge medicines to treat patients in America and around the world,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson.

In Wilson, North Carolina, Johnson & Johnson is breaking ground on its new, 500,000 square foot, state-of-the-art biologics manufacturing facility.

The North Carolina facility will enhance the company’s ability to produce next-generation medicines for cancer, immune-mediated, and neurological diseases globally, while supporting around 5,000 construction jobs and creating over 500 permanent positions. Additionally, it is expected to generate a $3 billion economic impact across the state within its first decade of operation.

Beyond the Wilson, North Carolina facility, the Company will invest further in the U.S. over the next four years, including three new advanced manufacturing sites, expansions across its Innovative Medicine and MedTech businesses, and extensive R&D infrastructure to advance treatments in oncology, neuroscience, immunology, cardiovascular disease, and robotic surgery. Additional technology investments will accelerate drug discovery, enhance workforce training, and optimize operations. These efforts will create high-tech jobs and strengthen the Company’s annual U.S. economic impact, already exceeding $100 billion.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.